SAN DIEGO, May 28, 2021 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) today announced that it will
participate at the following investor conferences:
- The Goldman Sachs 42nd Annual Global Healthcare
Conference on Tuesday, June 8,
2021 at 11:20 a.m. ET /
8:20 a.m. ET. Dr. Helen Torley, president and chief executive
officer, will represent the company in a fireside chat.
- The JMP Securities Life Sciences Conference on
Thursday, June 17, 2021 at
3:00 p.m. ET / 12:00 p.m. PT. Elaine
Sun, senior vice president and chief financial officer, will
represent the company in a fireside chat.
These conferences will be held virtually. Live webcasts of the
applicable presentations will be accessible on the company's
website www.halozyme.com under the investors section and an
archived recording will be available on the website for
approximately one month following each presentation.
About Halozyme
Halozyme is a biopharmaceutical
company bringing disruptive solutions to significantly improve
patient experiences and outcomes for emerging and established
therapies. Halozyme advises and supports its biopharmaceutical
partners in key aspects of new drug development with the goal of
improving patients' lives while helping its partners achieve global
commercial success. As the innovators of the ENHANZE®
technology, which can reduce hours-long treatments to a matter of
minutes, Halozyme's commercially-validated solution has positively
impacted more than 500,000 patient lives via five commercialized
products across more than 100 global markets. Halozyme and its
world-class partners are currently advancing multiple therapeutic
programs intended to deliver innovative therapies, with the
potential to improve the lives of patients around the globe.
Halozyme's proprietary enzyme rHuPH20 forms the basis of the
ENHANZE® technology and is used to facilitate the
delivery of injected drugs and fluids, potentially reducing the
treatment burden of other drugs to patients. Halozyme has licensed
its ENHANZE® technology to leading pharmaceutical and
biotechnology companies including Roche, Baxalta, Pfizer, Janssen,
AbbVie, Lilly, Bristol-Myers Squibb, Alexion, argenx and Horizon
Therapeutics. Halozyme derives revenues from these collaborations
in the form of milestones and royalties as the Company's partners
make progress developing and commercializing their products being
developed with ENHANZE®. Halozyme is headquartered in
San Diego. For more information
visit www.halozyme.com.
Contact:
Al Kildani
Vice President, Investor Relations and Corporate
Communications
858-704-8122
ir@halozyme.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/halozyme-to-present-at-upcoming-investor-conferences-301301904.html
SOURCE Halozyme Therapeutics, Inc.